(0.05%) 5 472.17 points
(0.06%) 39 134 points
(0.38%) 17 784 points
(-0.05%) $80.79
(-3.66%) $2.66
(-0.76%) $2 313.10
(0.21%) $28.93
(3.61%) $1 022.00
(0.28%) $0.936
(0.70%) $10.68
(0.45%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada...
Stats | |
---|---|
今日成交量 | 3.91M |
平均成交量 | 2.05M |
市值 | 794.69M |
EPS | $-0.0668 ( Q3 | 2023-11-06 ) |
下一个收益日期 | ( $0 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-17.43 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.410 (2.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-08 | Akkaraju Srinivas | Sell | 640 688 | Common Stock |
2023-11-08 | Akkaraju Srinivas | Sell | 8 111 | Common Stock |
2023-11-08 | Akkaraju Srinivas | Sell | 12 089 | Option to Purchase Common Stock |
2023-11-08 | Akkaraju Srinivas | Sell | 12 790 | Option to Purchase Common Stock |
2023-11-08 | Akkaraju Srinivas | Sell | 12 547 | Option to Purchase Common Stock |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 1 646 020 |
音量 相关性
Intercept Pharmaceuticals 相关性 - 货币/商品
Intercept Pharmaceuticals 财务报表
Annual | 2022 |
营收: | $285.71M |
毛利润: | $284.73M (99.66 %) |
EPS: | $3.40 |
FY | 2022 |
营收: | $285.71M |
毛利润: | $284.73M (99.66 %) |
EPS: | $3.40 |
FY | 2021 |
营收: | $363.47M |
毛利润: | $360.37M (99.15 %) |
EPS: | $-2.88 |
FY | 2020 |
营收: | $312.69M |
毛利润: | $307.37M (98.30 %) |
EPS: | $-8.34 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。